The role of bile acid metabolism in bone and muscle: from analytics to mechanisms

References

• Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in malmö. Osteoporos Int. 2000;11(8):669–674. doi: 10.1007/s001980070064.
   PubMed Web of Science ®Google Scholar
• Melton LJ, Chrischilles EA, Cooper C, et al. How many women have osteoporosis? J Bone Miner Res. 1992;7(9):1005–1010. doi: 10.1002/jbmr.5650070902.
   PubMed Web of Science ®Google Scholar
• Curtis EM, van der Velde R, Moon RJ, et al. Epidemiology of fractures in the United Kingdom 1988–2012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone. 2016;87:19–26. doi: 10.1016/j.bone.2016.03.006.
   PubMed Web of Science ®Google Scholar
• Odén A, McCloskey EV, Kanis JA, et al. Burden of high fracture probability worldwide: secular increases 2010–2040. Osteoporos Int. 2015;26(9):2243–2248. doi: 10.1007/s00198-015-3154-6.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Melton LJI. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319):1761–1767. doi: 10.1016/S0140-6736(02)08657-9.
   PubMed Web of Science ®Google Scholar
• Autier P, Haentjens P, Bentin J, et al. Costs induced by hip fractures: a prospective controlled study in Belgium. Osteoporos Int. 2000;11(5):373–380. doi: 10.1007/s001980070102.
   PubMed Web of Science ®Google Scholar
• Cree M, Soskolne CL, Belseck E, et al. Mortality and institutionalization following hip fracture. J Am Geriatr Soc. 2000;48(3):283–288. doi: 10.1111/j.1532-5415.2000.tb02647.x.
   PubMed Web of Science ®Google Scholar
• Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002;162(19):2217–2222. doi: 10.1001/archinte.162.19.2217.
   PubMedGoogle Scholar
• Lee DY, Shin S. Association of sarcopenia with osteopenia and osteoporosis in community-dwelling older Korean adults: a cross-sectional study. J Clin Med. 2021;11(1):129. doi: 10.3390/jcm11010129.
   PubMed Web of Science ®Google Scholar
• Reiss J, Iglseder B, Alzner R, et al. Sarcopenia and osteoporosis are interrelated in geriatric inpatients. Z Gerontol Geriatr. 2019;52(7):688–693. doi: 10.1007/s00391-019-01553-z.
   PubMed Web of Science ®Google Scholar
• Locquet M, Beaudart C, Reginster J-Y, et al. Prevalence of concomitant bone and muscle wasting in elderly women from the sarcophage cohort: preliminary results. J Frailty Aging. 2017;6(1):18–23. doi: 10.14283/jfa.2016.111.
   PubMedGoogle Scholar
• Khongsri N, Tongsuntud S, Limampai P, et al. The prevalence of sarcopenia and related factors in a community-dwelling elders thai population. Osteoporos Sarcopenia. 2016;2(2):110–115. doi: 10.1016/j.afos.2016.05.001.
   PubMedGoogle Scholar
• Huo YR, Suriyaarachchi P, Gomez F, et al. Phenotype of osteosarcopenia in older individuals with a history of falling. J Am Med Dir Assoc. 2015;16(4):290–295. doi: 10.1016/j.jamda.2014.10.018.
   PubMed Web of Science ®Google Scholar
• Monaco D, Vallero M, Di Monaco F, et al. Prevalence of sarcopenia and its association with osteoporosis in 313 older women following a hip fracture. Arch Gerontol Geriatr. 2011;52(1):71–74. doi: 10.1016/j.archger.2010.02.002.
   PubMed Web of Science ®Google Scholar
• Clynes MA, Gregson CL, Bruyère O, et al. Osteosarcopenia: where osteoporosis and sarcopenia collide. Rheumatology. 2021;60(2):529–537. doi: 10.1093/rheumatology/keaa755.
   PubMed Web of Science ®Google Scholar
• Hirschfeld HP, Kinsella R, Duque G. Osteosarcopenia: where bone, muscle, and fat collide. Osteoporos Int. 2017;28(10):2781–2790. doi: 10.1007/s00198-017-4151-8.
   PubMed Web of Science ®Google Scholar
• He C, He W, Hou J, et al. Bone and muscle crosstalk in aging. Front Cell Dev Biol. 2020;8:585644. doi: 10.3389/fcell.2020.
   PubMed Web of Science ®Google Scholar
• Bettis T, Kim BJ, Hamrick MW. Impact of muscle atrophy on bone metabolism and bone strength: implications for muscle-bone crosstalk with aging and disuse. Osteoporos Int. 2018;29(8):1713–1720. doi: 10.1007/s00198-018-4570-1.
   PubMed Web of Science ®Google Scholar
• Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4(1):177–197. doi: 10.1002/cphy.c130024.
   PubMed Web of Science ®Google Scholar
• Lu K, Shi TS, Shen SY, et al. Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression. Cell Metab. 2022;34(3):441–457.e7. doi: 10.1016/j.cmet.2022.02.006.
   PubMed Web of Science ®Google Scholar
• Wang X, Wei W, Krzeszinski JY, et al. A liver-bone endocrine relay by IGFBP1 promotes osteoclastogenesis and mediates FGF21-induced bone resorption. Cell Metab. 2015;22(5):811–824. doi: 10.1016/j.cmet.2015.09.010.
   PubMed Web of Science ®Google Scholar
• Li Z, Wen X, Li N, et al. The roles of hepatokine and osteokine in liver-bone crosstalk: advance in basic and clinical aspects. Front Endocrinol. 2023;14:1149233. doi: 10.3389/fendo.2023.1149233.
   PubMed Web of Science ®Google Scholar
• Ehnert S, Aspera-Werz RH, Ruoß M, et al. Hepatic osteodystrophy-molecular mechanisms proposed to favor its development. Int J Mol Sci. 2019;20(10):2555. doi3390/ijms20102555. doi: 10.3390/ijms20102555.
   PubMed Web of Science ®Google Scholar
• Danford CJ, Trivedi HD, Bonder A. Bone health in patients with liver diseases. J Clin Densitom. 2020;23(2):212–222. doi: 10.1016/j.jocd.2019.01.004.
   PubMed Web of Science ®Google Scholar
• Guañabens N, Parés A. Liver and bone. Arch Biochem Biophys. 2010;503(1):84–94. doi: 10.1016/j.abb.2010.05.030.
   PubMed Web of Science ®Google Scholar
• Meyer F, Bannert K, Wiese M, et al. Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis. Int J Mol Sci. 2020;21(15):5357. doi: 10.3390/ijms21155357.
   PubMed Web of Science ®Google Scholar
• Dasarathy S. Etiology and management of muscle wasting in chronic liver disease. Curr Opin Gastroenterol. 2016;32(3):159–165. doi: 10.1097/MOG.0000000000000261.
   PubMed Web of Science ®Google Scholar
• Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care. 2009;32(Suppl 2):S237–S245. doi: 10.2337/dc09-s355.
   PubMedGoogle Scholar
• Di Gregorio MC, Cautela J, Galantini L. Physiology and physical chemistry of bile acids. Int J Mol Sci. 2021;22(4):1780. doi: 10.3390/ijms22041780.
   PubMed Web of Science ®Google Scholar
• Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7(8):678–693. doi: 10.1038/nrd2619.
   PubMed Web of Science ®Google Scholar
• Yang S, Li H, Gu Y, et al. The association between total bile acid and bone mineral density among patients with type 2 diabetes. Front Endocrinol. 2023;14:1153205. doi: 10.3389/fendo.2023.
   PubMedGoogle Scholar
• Zhao X, Liu Z, Sun F, et al. Bile acid detection techniques and bile acid-related diseases. Front Physiol. 2022;13:826740. doi: 10.3389/fphys.2022.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen Y, Luo Q. The association of serum total bile acids with bone mineral density in chinese adults aged 20–59: a retrospective cross-Sectional study. Front Endocrinol. 2022;13:817437. doi: 10.3389/fendo.2022.817437.
   PubMed Web of Science ®Google Scholar
• Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72(1):137–174. doi: 10.1146/annurev.biochem.72.121801.161712.
   PubMedGoogle Scholar
• Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003;83(2):633–671. doi: 10.1152/physrev.00027.2002.-Molecular.
   PubMed Web of Science ®Google Scholar
• Pandak WM, Bohdan P, Franklund C, et al. Expression of sterol 12α-hydroxylase alters bile acid pool composition in primary rat hepatocytes and in vivo. Gastroenterology. 2001;120(7):1801–1809. doi: 10.1053/gast.2001.24833.
   PubMed Web of Science ®Google Scholar
• Gälman C, Angelin B, Rudling M. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J Intern Med. 2011;270(6):580–588. doi: 10.1111/j.1365-2796.2011.02466.x.
   PubMed Web of Science ®Google Scholar
• Meier PJ, Stieger B. Bile salt transporters. Annu Rev Physiol. 2002;64(1):635–661. doi: 10.1146/annurev.physiol.64.082201.100300.
   PubMedGoogle Scholar
• Inagaki T, Moschetta A, Lee Y-K, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sciences. 2006;103:3920–3925. doi: 10.1073/pnas.0509592103.
   PubMed Web of Science ®Google Scholar
• Hofmann AF, Hagey LR. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res. 2014;55(8):1553–1595. doi: 10.1194/jlr.R049437.
   PubMed Web of Science ®Google Scholar
• Sjövall J. Fifty years with bile acids and steroids in health and disease. Lipids. 2004;39(8):703–722. doi: 10.1007/s11745-004-1288-1.
   PubMed Web of Science ®Google Scholar
• Shackleton C, Pozo OJ, Marcos J. GC/MS in recent years has defined the normal and clinically disordered steroidome: will it soon be surpassed by LC/tandem MS in this role? J Endocr Soc. 2018;2(8):974–996. doi: 10.1210/JS.2018-00135.
   PubMed Web of Science ®Google Scholar
• Simstich S, Fauler G. Bile acids. Mass spectrometry for lipidomics. 2023;2:509–529. doi: 10.1002/9783527836512.ch17.
   Google Scholar
• Amplatz B, Zöhrer E, Haas C, et al. Bile acid preparation and comprehensive analysis by high performance liquid chromatography–high-resolution mass spectrometry. Clin Chim Acta. 2017;464:85–92. doi: 10.1016/j.cca.2016.11.014.
   PubMed Web of Science ®Google Scholar
• Haange SB, Till A, Bergh PO, et al. Ring trial on quantitative assessment of bile acids reveals a method-and analyte-specific accuracy and reproducibility. Metabolites. 2022;12(7):583. doi: 10.3390/metabo12070583.
   PubMed Web of Science ®Google Scholar
• Prost JC, Brunner F, Bovet C, et al. A UHPLC–MS/MS method for the quantification of 7α-hydroxy-4-cholesten-3-one to assist in diagnosis of bile acid malabsorption. Clin Mass Spectrom. 2017;3:1–6. doi: 10.1016/j.clinms.2017.02.001.
   Google Scholar
• Hu T, Li H, Xu B, et al. Parallel derivatization strategy for comprehensive profiling of unconjugated and glycine-conjugated bile acids using ultra-high performance liquid chromatography-tandem mass spectrometry. J Steroid Biochem Mol Biol. 2021;214:105986. doi: 10.1016/j.jsbmb.2021.
   PubMed Web of Science ®Google Scholar
• Honda A, Yamashita K, Numazawa M, et al. Highly sensitive quantification of 7α-hydroxy-4-cholesten-3-one in human serum by LC-ESI-MS/MS. J Lipid Res. 2007;48(2):458–464. doi: 10.1194/jlr.D600032-JLR200.
   PubMed Web of Science ®Google Scholar
• Huang J, Bathena SPR, Csanaky IL, et al. Simultaneous characterization of bile acids and their sulfate metabolites in mouse liver, plasma, bile, and urine using LC-MS/MS. J Pharm Biomed Anal. 2011;55(5):1111–1119. doi: 10.1016/j.jpba.2011.03.035.
   PubMed Web of Science ®Google Scholar
• Shafaei A, Rees J, Christophersen CT, et al. Extraction and quantitative determination of bile acids in feces. Anal Chim Acta. 2021;1150:338224. doi: 10.1016/j.aca.2021.
   PubMed Web of Science ®Google Scholar
• Cai Y, Shen X, Lu L, et al. Bile acid distributions, sex-specificity, and prognosis in colorectal cancer. Biol Sex Differ. 2022;13(1):61. doi: 10.1186/s13293-022-00473-9.
   PubMed Web of Science ®Google Scholar
• Patton ME, Kelekar S, Taylor LJ, et al. Circulating bile acid levels direct sex-differences in liver cancer development. bioRxiv. 2020; doi: 10.1101/2020.06.25.172635.
   Google Scholar
• Xie G, Wang Y, Wang X, et al. Profiling of serum bile acids in a healthy Chinese population using UPLC-MS/MS. J Proteome Res. 2015;14(2):850–859. doi: 10.1021/pr500920q.
   PubMed Web of Science ®Google Scholar
• Fitzinger J, Rodriguez-Blanco G, Herrmann M, et al. Gender-specific bile acid profiles in non-alcoholic fatty liver disease. Nutrients. 2024;16(2):250. doi: 10.3390/nu16020250.
   PubMed Web of Science ®Google Scholar
• Kang L, Connolly TM, Weng N, et al. LC–MS/MS quantification of 7α-hydroxy-4-cholesten-3-one (C4) in rat and monkey plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1064:49–55. doi: 10.1016/j.jchromb.2017.09.006.
   PubMed Web of Science ®Google Scholar
• LeníĿek M, Vecka M, Žížalová K, et al. Comparison of simple extraction procedures in liquid chromatography–mass spectrometry based determination of serum 7α-hydroxy-4-cholesten-3-one, a surrogate marker of bile acid synthesis. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1033–1034:317–320. doi: 10.1016/j.jchromb.2016.08.046.
   PubMed Web of Science ®Google Scholar
• Griffiths WJ, Sjövall J. Bile acids: analysis in biological fluids and tissues. J Lipid Res. 2010;51(1):23–41. doi: 10.1194/jlr.R001941-JLR200.
   PubMed Web of Science ®Google Scholar
• Minato K, Suzuki M, Nagao H, et al. Development of analytical method for simultaneous determination of five rodent unique bile acids in rat plasma using ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;1002:399–410. doi: 10.1016/j.jchromb.2015.08.047.
   PubMed Web of Science ®Google Scholar
• Bobeldijk I, Hekman M, de Vries-van der Weij J, et al. Quantitative profiling of bile acids in biofluids and tissues based on accurate mass high resolution LC-FT-MS: compound class targeting in a metabolomics workflow. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;871(2):306–313. doi: 10.1016/j.jchromb.2008.05.008.
   PubMed Web of Science ®Google Scholar
• Zhu X, Xia EQ, Liu YG, et al. Characterization and quantification of representative bile acids in ileal contents and feces of diet-induced obese mice by UPLC-MS/MS. Chin J Anal Chem. 2023;51(3):100175. doi: 10.1016/j.cjac.2022.
   Web of Science ®Google Scholar
• Bathena SPR, Mukherjee S, Olivera M, et al. The profile of bile acids and their sulfate metabolites in human urine and serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;942–943:53–62. doi: 10.1016/j.jchromb.2013.10.019.
   PubMed Web of Science ®Google Scholar
• Asano T, Taki K, Kitamori K, et al. One-pot extraction and quantification method for bile acids in the rat liver by capillary liquid chromatography tandem mass spectrometry. ACS Omega. 2021;6(12):8588–8597. doi: 10.1021/acsomega.1c00403.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang X, Chen J, et al. Targeted metabolomics of sulfated bile acids in urine for the diagnosis and grading of intrahepatic cholestasis of pregnancy. Genes Dis. 2018;5(4):358–366. doi: 10.1016/j.gendis.2018.01.005.
   PubMed Web of Science ®Google Scholar
• Wu T, Yang M, Xu H, et al. Serum bile acid profiles improve clinical prediction of nonalcoholic fatty liver in T2DM patients. J Proteome Res. 2021;20(8):3814–3825. doi: 10.1021/acs.jproteome.1c00104.
   PubMed Web of Science ®Google Scholar
• Habler K, Koeppl B, Bracher F, et al. Targeted profiling of 24 sulfated and non-sulfated bile acids in urine using two-dimensional isotope dilution UHPLC-MS/MS. Clin Chem Lab Med. 2022;60(2):220–228. doi: 10.1515/cclm-2021-1111.
   PubMed Web of Science ®Google Scholar
• Choucair I, Nemet I, Li L, et al. Quantification of bile acids: a mass spectrometry platform for studying gut microbe connection to metabolic diseases. J Lipid Res. 2020;61(2):159–177. doi: 10.1194/jlr.RA119000311.
   PubMed Web of Science ®Google Scholar
• Steiner C, von Eckardstein A, Rentsch KM. Quantification of the 15 major human bile acids and their precursor 7α-hydroxy-4-cholesten-3-one in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(28):2870–2880. doi: 10.1016/j.jchromb.2010.08.045.
   PubMed Web of Science ®Google Scholar
• Ramos-Garcia V, Ten-Doménech I, Vento M, et al. Fast profiling of primary, secondary, conjugated, and sulfated bile acids in human urine and murine feces samples. Anal Bioanal Chem. 2023;415(20):4961–4971. doi: 10.1007/s00216-023-04802-8.
   PubMed Web of Science ®Google Scholar
• Wang YZ, Mei PC, Bai PR, et al. A strategy for screening and identification of new amino acid-conjugated bile acids with high coverage by liquid chromatography-mass spectrometry. Anal Chim Acta. 2023;1239:340691. doi: 10.1016/j.aca.2022.
   PubMed Web of Science ®Google Scholar
• Lee G, Lee H, Hong J, et al. Quantitative profiling of bile acids in rat bile using ultrahigh-performance liquid chromatography–orbitrap mass spectrometry: alteration of the bile acid composition with aging. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1031:37–49. doi: 10.1016/j.jchromb.2016.07.017.
   PubMed Web of Science ®Google Scholar
• Shi Y, Gao Y, Parys MV, et al. Definitive profiling of plasma bile acids as potential biomarkers for human liver diseases using UPLC-HRMS. Bioanalysis. 2018;10(12):917–932. doi: 10.4155/bio-2018-0018.
   PubMed Web of Science ®Google Scholar
• Jiang P, Sun Y, Cheng N. Liver metabolomic characterization of sophora flavescens alcohol extract-induced hepatotoxicity in rats through UPLC/LTQ-Orbitrap mass spectrometry. Xenobiotica. 2020;50(6):670–676. doi: 10.1080/00498254.2019.1687962.
   PubMed Web of Science ®Google Scholar
• Rago B, Tierney B, Rodrigues AD, et al. A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers. Bioanalysis. 2018;10(9):645–657. doi: 10.4155/bio-2017-0274.
   PubMed Web of Science ®Google Scholar
• Lin M, Chen X, Wang Z, et al. Global profiling and identification of bile acids by multi-dimensional data mining to reveal a way of eliminating abnormal bile acids. Anal Chim Acta. 2020;1132:74–82. doi: 10.1016/j.aca.2020.07.067.
   PubMed Web of Science ®Google Scholar
• Frommherz L, Bub A, Hummel E, et al. Age-related changes of plasma bile acid concentrations in healthy adults-results from the cross-sectional karmen study. PLOS One. 2016;11(4):e0153959. doi: 10.1371/journal.pone.0153959.
   PubMed Web of Science ®Google Scholar
• de Paiva MJN, Menezes HC, da Silva C, et al. New method for the determination of bile acids in human plasma by liquid-phase microextraction using liquid chromatography-ion-trap-time-of-flight mass spectrometry. J Chromatogr A. 2015;1388:102–109. doi: 10.1016/j.chroma.2015.02.016.
   PubMed Web of Science ®Google Scholar
• Poland JC, Leaptrot KL, Sherrod SD, et al. Collision cross section conformational analyses of bile acids via ion Mobility-Mass spectrometry. J Am Soc Mass Spectrom. 2020;31(8):1625–1631. doi: 10.1021/jasms.0c00015.
   Web of Science ®Google Scholar
• Kanu AB, Dwivedi P, Tam M, et al. Ion mobility-mass spectrometry. J Mass Spectrom. 2008;43(1):1–22. doi: 10.1002/jms.1383.
   PubMed Web of Science ®Google Scholar
• Draper J, Lloyd AJ, Goodacre R, et al. Flow infusion electrospray ionisation mass spectrometry for high throughput, non-targeted metabolite fingerprinting: a review. Metabolomics. 2013;9(S1):4–29. doi: 10.1007/s11306-012-0449-x.
   Google Scholar
• Setchell KDR, Heubi E. Defects in bile acid biosynthesis - diagnosis and treatment. J Pediatr Gastroenterol Nutr. 2006;43(Suppl 1):S17–S22. doi: 10.1097/01.mpg.0000226386.79483.7b.
   PubMedGoogle Scholar
• Züllig T, Köfeler HC. High resolution mass spectrometry in lipidomics. Mass Spectrom Rev. 2021;40(3):162–176. doi: 10.1002/mas.21627.
   PubMed Web of Science ®Google Scholar
• Blaženović I, Kind T, Ji J, et al. Software tools and approaches for compound identification of LC-MS/MS data in metabolomics. Metabolites. 2018;8(2):31. doi: 10.3390/metabo8020031.
   PubMed Web of Science ®Google Scholar
• Ma Y, Cao Y, Song X, et al. BAFinder: a software for unknown bile acid identification using accurate mass LC-MS/MS in positive and negative modes. Anal Chem. 2022;94(16):6242–6250. doi: 10.1021/acs.analchem.1c05648.
   PubMed Web of Science ®Google Scholar
• Jacob M, Lopata AL, Dasouki M, et al. Metabolomics toward personalized medicine. Mass Spectrom Rev. 2019;38(3):221–238. doi: 10.1002/mas.21548.
   Google Scholar
• Quinn RA, Melnik AV, Vrbanac A, et al. Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020;579(7797):123–129. doi: 10.1038/s41586-020-2047-9.
   PubMed Web of Science ®Google Scholar
• Mancin L, Wu GD, Paoli A. Gut microbiota–bile acid–skeletal muscle axis. Trends Microbiol. 2023;31(3):254–269. doi: 10.1016/j.tim.2022.10.003.
   PubMed Web of Science ®Google Scholar
• De Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013;17(5):657–669. doi: 10.1016/j.cmet.2013.03.013.
   PubMed Web of Science ®Google Scholar
• Kaeslin J, Zenobi R. Resolving isobaric interferences in direct infusion tandem mass spectrometry. Rapid Commun Mass Spectrom. 2022;36(9):e9266. doi: 10.1002/rcm.9266.
   PubMed Web of Science ®Google Scholar
• Wang M, Wang C, Han RH, et al. Novel advances in shotgun lipidomics for biology and medicine. Prog Lipid Res. 2016;61:83–108. doi: 10.1016/j.plipres.2015.12.002.
   PubMed Web of Science ®Google Scholar
• Pöhö P, Lipponen K, Bespalov MM, et al. Comparison of liquid chromatography-mass spectrometry and direct infusion microchip electrospray ionization mass spectrometry in global metabolomics of cell samples. Eur J Pharm Sci. 2019;138:104991. doi: 10.1016/j.ejps.2019.
   PubMed Web of Science ®Google Scholar
• Southam AD, Weber RJM, Engel J, et al. A complete workflow for high-resolution spectral-stitching nanoelectrospray direct-infusion mass-spectrometry-based metabolomics and lipidomics. Nat Protoc. 2017;12(2):310–328–328. doi: 10.1038/nprot.2016.156.
   Web of Science ®Google Scholar
• Fiorucci S, Distrutti E, Carino A, et al. Bile acids and their receptors in metabolic disorders. Prog Lipid Res. 2021;82:101094. doi: 10.1016/j.plipres.2021.101094.
   PubMed Web of Science ®Google Scholar
• Sato H, Genet C, Strehle A, et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun. 2007;362(4):793–798. doi: 10.1016/j.bbrc.2007.06.130.
   PubMed Web of Science ®Google Scholar
• Sorrentino G, Perino A, Yildiz E, et al. Bile acids signal via TGR5 to activate intestinal stem cells and epithelial regeneration. Gastroenterology. 2020;159(3):956–968.e8. doi: 10.1053/j.gastro.2020.05.067.
   PubMed Web of Science ®Google Scholar
• Molinaro A, Wahlström A, Marschall HU. Role of bile acids in metabolic control. Trends Endocrinol Metab. 2018;29(1):31–41. doi: 10.1016/j.tem.2017.11.002.
   PubMed Web of Science ®Google Scholar
• Chávez-Talavera O, Tailleux A, Lefebvre P, et al. Bile acids in meta-inflammatory disorders. Gastroenterology. 2017;152(7):1679–1694.e3. doi: 10.1053/j.gastro.2017.01.055ï.
   PubMed Web of Science ®Google Scholar
• Keitel V, Kubitz R, Häussinger D. Endocrine and paracrine role of bile acids. World J Gastroenterol. 2008;14(37):5620–5629. doi: 10.3748/wjg.14.5620.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Bouscarel B. Bile acids and signal transduction: role in glucose homeostasis. Cell Signal. 2008;20(12):2180–2197. doi: 10.1016/j.cellsig.2008.06.014.
   PubMed Web of Science ®Google Scholar
• Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. Embo J. 2006;25(7):1419–1425. doi: 10.1038/sj.emboj.7601049.
   PubMed Web of Science ®Google Scholar
• Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284(5418):1365–1368. doi: 10.1126/science.284.5418.1365.
   PubMed Web of Science ®Google Scholar
• Li T, Chiang JYL. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014;66(4):948–983. doi: 10.1124/pr.113.008201.
   PubMed Web of Science ®Google Scholar
• Holter MM, Chirikjian MK, Govani VN, et al. Tgr5 signaling in hepatic metabolic health. Nutrients. 2020;12(9):2598. doi: 10.3390/nu12092598.
   PubMed Web of Science ®Google Scholar
• Keitel V, Häussinger D. Role of TGR5 (GPBAR1) in liver disease. Semin Liver Dis. 2018;38(4):333–339. doi: 10.1055/s-0038-1669940.
   PubMed Web of Science ®Google Scholar
• Shi Y, Su W, Zhang L, et al. TGR5 regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP3 inflammasome activation. Front Immunol. 2020;11:609060. doi: 10.3389/fimmu.2020.609060.
   PubMed Web of Science ®Google Scholar
• Zhou H, Zhou S, Shi Y, et al. TGR5/cathepsin E signaling regulates macrophage innate immune activation in liver ischemia and reperfusion injury. Am J Transplant. 2021;21(4):1453–1464. doi: 10.1111/ajt.16327.
   PubMed Web of Science ®Google Scholar
• Asgharpour A, Kumar D, Sanyal A. Bile acids: emerging role in management of liver diseases. Hepatol Int. 2015;9(4):527–533. doi: 10.1007/s12072-015-9656-7.
   PubMed Web of Science ®Google Scholar
• Miller NE, Nestel PJ. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hyperglyceridaemia. Lancet. 1974;2(7886):929–931. doi: 10.1016/s0140-6736(74)91134-9.
   PubMed Web of Science ®Google Scholar
• Hirokane H, Nakahara M, Tachibana S, et al. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem. 2004;279(44):45685–45692. doi: 10.1074/jbc.M404255200.
   PubMed Web of Science ®Google Scholar
• Camarri E, Fici F, Marcolongo R. Influence of chenodeoxycholic acid on serum triglycerides in patients with primary hypertriglyceridemia. Int J Clin Pharmacol Biopharm. 1978;16:523–526.
   PubMedGoogle Scholar
• Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439(7075):484–489. doi: 10.1038/nature04330.
   PubMed Web of Science ®Google Scholar
• Alekos NS, Moorer MC, Riddle RC. Dual effects of lipid metabolism on osteoblast function. Front Endocrinol. 2020;11:578194. doi: 10.3389/fendo.2020.578194.
   PubMed Web of Science ®Google Scholar
• Kim G, Kang SH, Kim MY, et al. Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis. PLOS One. 2017;12(10):e0186990. doi1371/journal.pone.0186990. doi: 10.1371/journal.pone.0186990.
   PubMed Web of Science ®Google Scholar
• Akhmedov D, Berdeaux R. The effects of obesity on skeletal muscle regeneration. Front Physiol. 2013;4 doi: 10.3389/fphys.2013.00:.371.
   PubMed Web of Science ®Google Scholar
• Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus a short-term, double-blind, crossover trial. Ann Intern Med. 1994;121(6):416–422. doi: 10.7326/0003-4819-121-6-199409150-00004.
   PubMed Web of Science ®Google Scholar
• Angelin B, Leijd B, Hultcrantz R, et al. Increased turnover of very low density lipoprotein triglyceride during treatment with cholestyramine in familial hypercholesterolaemia. J Intern Med. 1990;227(3):201–206. doi: 10.1111/j.1365-2796.1990.tb00143.x.
   PubMed Web of Science ®Google Scholar
• Kast HR, Nguyen CM, Sinal CJ, et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol. 2001;15(10):1720–1728. doi: 10.1210/mend.15.10.0712.
   PubMed Web of Science ®Google Scholar
• Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol. 2012;13(4):213–224. doi: 10.1038/nrm3312.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Edwards PA. FXR signaling in metabolic disease. FEBS Lett. 2008;582(1):10–18. doi: 10.1016/j.febslet.2007.11.015.
   PubMed Web of Science ®Google Scholar
• Ghosh Laskar M, Eriksson M, Rudling M, et al. Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III. J Intern Med. 2017;281(6):575–585. doi: 10.1111/joim.12594.
   PubMed Web of Science ®Google Scholar
• Yamagata K, Daitoku H, Shimamoto Y, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem. 2004;279(22):23158–23165. doi: 10.1074/jbc.M314322200.
   PubMed Web of Science ®Google Scholar
• Claudel T, Inoue Y, Barbier O, et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology. 2003;125(2):544–555. doi: 10.1016/S0016-5085(03)00896-5.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004;113(10):1408–1418. doi: 10.1172/jci200421025.
   PubMed Web of Science ®Google Scholar
• Camarri E, Marcolongo R, Zaccherotti L, et al. The hypotriglyceridemic effect of chenodeoxycholic acid in type IV hyperlipemia. Biomedicine. 1978;29:193–198.
   PubMedGoogle Scholar
• Cipriani C, Colangelo L, Santori R, et al. The interplay between bone and glucose metabolism. Front Endocrinol. 2020;11 doi: 10.3389/fendo.2020.00:.122.
   PubMed Web of Science ®Google Scholar
• Lee WC, Guntur AR, Long F, et al. Energy metabolism of the osteoblast: implications for osteoporosis. Endocr Rev. 2017;38(3):255–266. doi: 10.1210/er.2017-00064.
   PubMed Web of Science ®Google Scholar
• Daily JW, Park S. Sarcopenia Is a cause and consequence of metabolic dysregulation in aging humans: effects of gut dysbiosis, glucose dysregulation, diet and lifestyle. Cells. MDPI. 2022;11(3):030338. doi: 10.3390/cells11030338.
   Web of Science ®Google Scholar
• Baquet A, Hue L, Meijer AJ, et al. Swelling of rat hepatocytes stimulates glycogen synthesis. J Biol Chem. 1990;265(2):955–959. doi: 10.1016/S0021-9258(19)40142-7.
   PubMed Web of Science ®Google Scholar
• Saha N, Stoll B, Lang F, et al. Effect of anisotonic cell‐volume modulation on glutathione‐S‐conjugate release, t‐butylhydroperoxide metabolism and the pentose‐phosphate shunt in perfused rat liver. Eur J Biochem. 1992;209(1):437–444. doi: 10.1111/j.1432-1033.1992.tb17307.x.
   PubMedGoogle Scholar
• Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116(4):1102–1109. doi: 10.1172/JCI25604.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ying Lee F, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 2006;103(4):1006–1011. doi: 10.1073/pnas.0506982103.
   PubMed Web of Science ®Google Scholar
• De Fabiani E, Mitro N, Gilardi F, et al. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem. 2003;278(40):39124–39132. doi: 10.1074/jbc.M305079200.
   PubMed Web of Science ®Google Scholar
• Newsome WP, Warskulat U, Noe B, et al. Modulation of phosphoenolpyruvate carboxykinase mRNA levels by the hepatocellular hydration state. Biochem J. 1994;304(Pt 2):555–560. doi: 10.1042/bj3130697.
   PubMedGoogle Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised european consensus on definition and diagnosis. Age Ageing. 2019;48(4):601–631. doi: 10.1093/ageing/afz046.
   PubMed Web of Science ®Google Scholar
• Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 2012;26(4):312–324. doi: 10.1101/gad.184788.111.
   PubMed Web of Science ®Google Scholar
• Schaap FG. Role of fibroblast growth factor 19 in the control of glucose homeostasis. Curr Opin Clin Nutr Metab Care. 2012;15(4):386–391. doi: 10.1097/MCO.0b013e3283547171.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Castellani LW, Sinal CJ, et al. Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 2004;18(2):157–169. doi: 10.1101/gad.1138104.
   PubMed Web of Science ®Google Scholar
• Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331(6024):1621–1624. 1979 doi: 10.1126/science.1198363.
   PubMed Web of Science ®Google Scholar
• Duran-Sandoval D, Le Mautino G, Ve Martin G, et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes. 2004;53(4):890–898. doi: 10.2337/diabetes.53.4.890.
   PubMed Web of Science ®Google Scholar
• Son SW, Song DS, Chang UI, et al. Definition of sarcopenia in chronic liver disease. Life. 2021;11(4):11. doi: 10.3390/life11040349.
   Google Scholar
• Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005;329(1):386–390. doi: 10.1016/j.bbrc.2005.01.139.
   PubMed Web of Science ®Google Scholar
• Tajiri K, Shimizu Y. Branched-chain amino acids in liver diseases. Transl Gastroenterol Hepatol. 2018;3:47–47. doi: 10.21037/tgh.2018.07.06.
   PubMed Web of Science ®Google Scholar
• Okubo T, Atsukawa M, Tsubota A, et al. Relationship between serum vitamin D level and sarcopenia in chronic liver disease. Hepatol Res. 2020;50(5):588–597. doi: 10.1111/hepr.13485.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Hara N, Sugimoto R, et al. The associations between circulating bile acids and the muscle volume in patients with non-alcoholic fatty liver disease (NAFLD). Intern Med. 2017;56(7):755–762. doi: 10.2169/internalmedicine.56.7796.
   PubMed Web of Science ®Google Scholar
• Allen SL, Quinlan JI, Dhaliwal A, et al. Sarcopenia in chronic liver disease: mechanisms and countermeasures. Am J Physiol Gastrointest Liver Physiol. 2021;320(3):G241–G257. doi: 10.1152/ajpgi.00373.2020.
   PubMed Web of Science ®Google Scholar
• Graf J, Haddad P, Haeussinger D, et al. Cell volume regulation in liver. Ren Physiol Biochem. 1988;11(3-5):202–220. doi:10.1059/000173163.
   PubMedGoogle Scholar
• Häussinger D, Lang F. Cell volume in the regulation of hepatic function: a mechanism for metabolic control. Biochim Biophys Acta. 1991;1071(4):331–350. doi: 10.1016/0304-4157(91)90001-d.
   PubMedGoogle Scholar
• Häussinger D. The role of cellular hydration in the regulation of cell function. Biochem J. 1996;313 (Pt 3)(Pt 3):697–710. doi: 10.1042/bj3130697.
   PubMedGoogle Scholar
• Pols TWH, Noriega LG, Nomura M, et al. The bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis. 2011;29(1):37–44. doi: 10.1159/000324126.
   PubMed Web of Science ®Google Scholar
• Campos F, Abrigo J, Aguirre F, et al. Sarcopenia in a mice model of chronic liver disease: role of the ubiquitin–proteasome system and oxidative stress. Pflugers Arch. 2018;470(10):1503–1519. doi: 10.1007/s00424-018-2167-3.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Kuboyama A, Mita M, et al. The exercise-inducible bile acid receptor Tgr5 improves skeletal muscle function in mice. J Biol Chem. 2018;293(26):10322–10332. doi: 10.1074/jbc.RA118.002733.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020;9(9):1970. doi: 10.3390/cells9091970.
   PubMed Web of Science ®Google Scholar
• Aguirre F, Abrigo J, Gonzalez F, et al. Protective effect of angiotensin 1–7 on sarcopenia induced by chronic liver disease in mice. Int J Mol Sci. 2020;21(11):3891. doi: 10.3390/ijms21113891.
   PubMed Web of Science ®Google Scholar
• Hara N, Iwasa M, Sugimoto R, et al. Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis. Intern Med. 2016;55(8):863–870. doi: 10.2169/internalmedicine.55.5676.
   PubMedGoogle Scholar
• Ebadi M, Bhanji RA, Mazurak VC, et al. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol. 2019;54(10):845–859. doi: 10.1007/s00535-019-01605-6.
   PubMed Web of Science ®Google Scholar
• Abrigo J, Olguín H, Gutierrez D, et al. Bile acids induce alterations in mitochondrial function in skeletal muscle fibers. Antioxidants. 2022;11(9):1706. doi: 10.3390/antiox11091706.
   Web of Science ®Google Scholar
• Abrigo J, Campos F, Gonzalez F, et al. Sarcopenia induced by chronic liver disease in mice requires the expression of the bile acids membrane receptor tgr5. Int J Mol Sci. 2020;21(21):7922. doi: 10.3390/ijms21217922.
   PubMed Web of Science ®Google Scholar
• Orozco-Aguilar J, Tacchi F, Aguirre F, et al. Ursodeoxycholic acid induces sarcopenia associated with decreased protein synthesis and autophagic flux. Biol Res. 2023;56(1):28. doi: 10.1186/s40659-023-00431-8.
   PubMed Web of Science ®Google Scholar
• Yang F, Mao C, Guo L, et al. Structural basis of GPBAR activation and bile acid recognition. Nature. 2020;587(7834):499–504. doi: 10.1038/s41586-020-2569-1.
   PubMed Web of Science ®Google Scholar
• Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020;21(4):183–203. doi: 10.1038/s41580-019-0199-y.
   PubMed Web of Science ®Google Scholar
• Tamai Y, Eguchi A, Shigefuku R, et al. Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans. Elife. 2022;11:1–16. doi: 10.7554/eLife.80638.
   PubMed Web of Science ®Google Scholar
• Marques J, Shokry E, Uhl O, et al. Sarcopenia: investigation of metabolic changes and its associated mechanisms. Skelet Muscle. 2023;13(1):2. doi: 10.1186/s13395-022-00312-w.
   PubMed Web of Science ®Google Scholar
• Aliwa B, Horvath A, Traub J, et al. Altered gut microbiome, bile acid composition and metabolome in sarcopenia in liver cirrhosis. J Cachexia Sarcopenia Muscle. 2023;14(6):2676–2691. doi: 10.1002/jcsm.13342.
   PubMed Web of Science ®Google Scholar
• Lee Y-H, Kim SU, Song K, et al. Sarcopenia Is associated With significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: nationwide surveys (KNHANES 2008-2011). Hepatology. 2016;63(3):776–786. doi: 10.1002/hep.28376/suppinfo.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298(5):714–719. doi: 10.1016/s0006-291x(02)02550-0.
   PubMed Web of Science ®Google Scholar
• Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278(11):9435–9440. doi: 10.1074/jbc.M209706200.
   PubMed Web of Science ®Google Scholar
• Basuray S, Smagris E, Cohen JC, et al. The PNPLA3 variant associated With fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology. 2017;66(4):1111–1124. doi: 10.1002/hep.29273/suppinfo.
   PubMed Web of Science ®Google Scholar
• Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011;6(1):121–145. doi: 10.1146/annurev-pathol-011110-130203.
   PubMedGoogle Scholar
• Robling AG, Bonewald LF. The osteocyte: new insights. Annu Rev Physiol. 2020;82(1):485–506. doi: 10.1146/annurev-physiol-021119-034332.
   PubMedGoogle Scholar
• Arai Y, Park H, Park S, et al. Bile acid-based dual-functional prodrug nanoparticles for bone regeneration through hydrogen peroxide scavenging and osteogenic differentiation of mesenchymal stem cells. J Control Release. 2020;328:596–607. doi: 10.1016/j.jconrel.2020.09.023.
   PubMed Web of Science ®Google Scholar
• Id Boufker H, Lagneaux L, Fayyad-Kazan H, et al. Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts. Bone. 2011;49(6):1219–1231. doi: 10.1016/j.bone.2011.08.013.
   PubMed Web of Science ®Google Scholar
• Wang Q, Wang G, Wang B, et al. Activation of TGR5 promotes osteoblastic cell differentiation and mineralization. Biomed Pharmacother. 2018;108:1797–1803. doi: 10.1016/j.biopha.2018.08.093.
   PubMed Web of Science ®Google Scholar
• Rourke JL, Hu Q, Screaton RA. AMPK and friends: central regulators of β cell biology. Trends Endocrinol Metab. 2018;29(2)Elsevier Inc:111–122. doi: 10.1016/j.tem.2017.11.007.
   PubMed Web of Science ®Google Scholar
• Zhao YX, Song YW, Zhang L, et al. Association between bile acid metabolism and bone mineral density in postmenopausal women. Clinics. 2020;75 doi: 10.6061/clinics/2020/:.e1486.
   PubMed Web of Science ®Google Scholar
• Ruiz-Gaspà S, Guañabens N, Enjuanes A, et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest. 2010;40(1):25–34. doi: 10.1111/j.1365-2362.2009.02230.x.
   PubMed Web of Science ®Google Scholar
• Kuchuk NO, Pluijm SMF, Van Schoor NM, et al. Relationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older persons. J Clin Endocrinol Metab. 2009;94(4):1244–1250. doi: 10.1210/jc.2008-1832.
   PubMed Web of Science ®Google Scholar
• Bischoff SC, Bernal W, Dasarathy S, et al. ESPEN practical guideline: clinical nutrition in liver disease. Clin Nutr. 2020;39(12):3533–3562. doi: 10.1016/j.clnu.2020.09.001.
   PubMed Web of Science ®Google Scholar
• Cha BH, Jung MJ, Moon BK, et al. Administration of tauroursodeoxycholic acid enhances osteogenic differentiation of bone marrow-derived mesenchymal stem cells and bone regeneration. Bone. 2016;83:73–81. doi: 10.1016/j.bone.2015.10.011.
   PubMed Web of Science ®Google Scholar
• Ahn TK, Kim KT, Joshi HP, et al. Therapeutic potential of tauroursodeoxycholic acid for the treatment of osteoporosis. Int J Mol Sci. 2020;21(12):4274. doi: 10.3390/ijms21124274.
   PubMed Web of Science ®Google Scholar
• Cho SW, An JH, Park H, et al. Positive regulation of osteogenesis by bile acid through FXR. J Bone Miner Res. 2013;28(10):2109–2121. doi: 10.1002/jbmr.1961.
   PubMed Web of Science ®Google Scholar
• Li Z, Huang J, Wang F, et al. Dual targeting of bile acid receptor-1 (TGR5) and farnesoid X receptor (FXR) prevents Estrogen-Dependent bone loss in mice. J Bone Miner Res. 2019;34(4):765–776. doi: 10.1002/jbmr.3652.
   PubMed Web of Science ®Google Scholar
• Ruiz-Gaspà S, Guañabens N, Jurado S, et al. Bilirubin and bile acids in osteocytes and bone tissue. Potential role in the cholestatic-induced osteoporosis. Liver Int. 2020;40(11):2767–2775. doi: 10.1111/liv.14630.
   PubMed Web of Science ®Google Scholar
• Zheng T, Kang J-H, Sim J-S, et al. The farnesoid X receptor negatively regulates osteoclastogenesis in bone remodeling and pathological bone loss. Oncotarget. 2017;8(44):76558–76573. doi: 10.18632/oncotarget.20576.
   PubMedGoogle Scholar
• Uchida K, Chikai T, Takase H, et al. Age-related changes of bile acid metabolism in rats. Arch Gerontol Geriatr. 1990;10(1):37–48. doi: 10.1016/0167-4943(90)90042-5.
   PubMed Web of Science ®Google Scholar
• Chen H, Ma J, Ma X. Administration of tauroursodeoxycholic acid attenuates dexamethasone-induced skeletal muscle atrophy. Biochem Biophys Res Commun. 2021;570:96–102. doi: 10.1016/j.bbrc.2021.06.102.
   PubMed Web of Science ®Google Scholar
• Vidal M, Thibodaux RJ, Neira LFV, et al. Osteoporosis: a clinical and pharmacological update. Clin Rheumatol. 2019;38(2):385–395. doi: 10.1007/s10067-018-4370-1.
   PubMed Web of Science ®Google Scholar
• Deng D, Pan C, Wu Z, et al. An integrated metabolomic study of osteoporosis: discovery and quantification of hyocholic acids as candidate markers. Front Pharmacol. 2021;12:725341. doi: 10.3389/fphar.2021.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Shen H, Su KJ, et al. Metabolomic profiles associated with bone mineral density in US caucasian women. Nutr Metab. 2018;15(1):57. doi: 10.1186/s12986-018-0296-5.
   Google Scholar
• Ewang-Emukowhate M, Alaghband-Zadeh J, Vincent RP, et al. An association between post-meal bile acid response and bone resorption in normal subjects. Ann Clin Biochem. 2013;50(Pt 6):558–563. doi: 10.1177/0004563213482891.
   PubMed Web of Science ®Google Scholar
• Yang F, Xu W, Wu L, et al. NTCP deficiency affects the levels of circulating bile acids and induces osteoporosis. Front Endocrinol. 2022;13:898750. doi: 10.3389/fendo.2022.
   PubMed Web of Science ®Google Scholar
• Stürznickel J, Behler-Janbeck F, Baranowsky A, et al. Increased concentrations of conjugated bile acids are associated with osteoporosis in PSC patients. Sci Rep. 2022;12(1):16491. doi: 10.1038/s41598-022-20351-z.
   PubMed Web of Science ®Google Scholar
• Guañabens N, Parés A. Osteoporosis in chronic liver disease. Liver Int. 2018;38(5):776–785. doi: 10.1111/liv.13730.
   PubMed Web of Science ®Google Scholar
• Guyton JR, Goldberg AC. Bile acid sequestrants. In: Clinical lipidology: a companion to braunwald’s heart disease. Philadelphia, USA: Elsevier Inc. 2009. p. 281–287.
   Google Scholar
• Chiang JYL. Bile acid metabolism and signaling in liver disease and therapy. Liver Res. 2017;1(1):3–9. doi: 10.1016/j.livres.2017.05.001.
   PubMedGoogle Scholar
• Li T, Chiang JYL. Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease. Hepatobiliary Surg Nutr. 2020;9(2):152–169. doi: 10.21037/hbsn.2019.09.03.
   PubMed Web of Science ®Google Scholar
• Dutta M, Cai J, Gui W, et al. A review of analytical platforms for accurate bile acid measurement. Anal Bioanal Chem. 2019;411(19):4541–4549. doi: 10.1007/s00216-019-01890-3.
   PubMed Web of Science ®Google Scholar